Last reviewed · How we verify
Ginkgolides Meglumine Injection
At a glance
| Generic name | Ginkgolides Meglumine Injection |
|---|---|
| Sponsor | Jiangsu Kanion Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
- A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke. (PHASE2)
- The Effect of Ginkgolide on Clinical Improvement of Patients With Acute Ischemic Stroke (PHASE2, PHASE3)
- Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke (NA)
- A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke. (PHASE4)
- A Pilot Study for Ginkgolides Meglumine Injection Skin Testing. (PHASE4)
- A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam (PHASE4)
- Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: